Form 4: Ginkgo Bioworks CFO Executes Sell-to-Cover Transaction

Ginkgo Bioworks CFO Steven P. Coen sold shares to satisfy tax withholding obligations following the vesting of restricted stock units.

Summary

• CFO Steven P. Coen acquired 743 shares of Class A Common Stock through the vesting of restricted stock units (RSUs) on April 16, 2026.
• The reporting person sold 324 shares on April 17, 2026, at a price of $7.952 per share.
• The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, the reporting person holds 50,268 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative requirement for tax obligations rather than a strategic market move.

Positives

• The transaction was non-discretionary and strictly for tax compliance purposes, indicating no change in the executive's long-term outlook on the company.

Negatives

• The transaction resulted in a net reduction of the executive's total share ownership.

Risks

• Reliance on equity-based compensation creates potential for future sell-to-cover transactions that may impact market sentiment.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The filing notes that sales to cover tax withholding obligations do not represent discretionary trades by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard administrative procedures for corporate executives receiving equity compensation and generally do not signal a change in management confidence.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for executive compensation tax handling, consistent with peers in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited in volume.

Next Steps

• Continued vesting of remaining RSUs according to the established schedule.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Insider Trading, Form 4, CFO, Equity Compensation